← Back to Search

Monoclonal Antibodies

JNJ-77242113 for Plaque Psoriasis (FRONTIER 2 Trial)

Phase 2
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 40
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called JNJ-77242113 for people with moderate-to-severe plaque psoriasis. These patients often need better treatments. The drug aims to improve their skin by changing how their immune system works.

Eligible Conditions
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 40
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 40 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 36
Secondary study objectives
Change From Baseline in PASI Total Score at Week 36
Change from Baseline in PSSD Signs Score at Week 36
Change from Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 36
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Group I: Group 6: JNJ-77242113 Dose 3 QDExperimental Treatment1 Intervention
Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
Group II: Group 5: JNJ-77242113 Dose 3 BIDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.
Group III: Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)Experimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.
Group IV: Group 3: JNJ-77242113 Dose 3 QDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
Group V: Group 2: JNJ-77242113 Dose 2 QDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.
Group VI: Group 1: JNJ-77242113 Dose 1 Once Daily (QD)Experimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JNJ-77242113
2022
Completed Phase 2
~640

Find a Location

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
1,007 Previous Clinical Trials
6,402,143 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
772 Previous Clinical Trials
3,980,170 Total Patients Enrolled

Media Library

Plaque Psoriasis Research Study Groups: Group 1: JNJ-77242113 Dose 1 Once Daily (QD), Group 2: JNJ-77242113 Dose 2 QD, Group 3: JNJ-77242113 Dose 3 QD, Group 4: JNJ-77242113 Dose 1 Twice Daily (BID), Group 5: JNJ-77242113 Dose 3 BID, Group 6: JNJ-77242113 Dose 3 QD
Plaque Psoriasis Clinical Trial 2023: JNJ-77242113 Highlights & Side Effects. Trial Name: NCT05364554 — Phase 2
~65 spots leftby Dec 2025